Segal A - Search Results

1

Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma.

Creaney J, Yeoman D, Demelker Y, Segal A, Musk AW, Skates SJ, Robinson BW. Creaney J, et al. Among authors: segal a. J Thorac Oncol. 2008 Aug;3(8):851-7. doi: 10.1097/JTO.0b013e318180477b. J Thorac Oncol. 2008. PMID: 18670302 Free article.

2

A novel prognostic model for malignant mesothelioma incorporating quantitative FDG-PET imaging with clinical parameters.

Nowak AK, Francis RJ, Phillips MJ, Millward MJ, van der Schaaf AA, Boucek J, Musk AW, McCoy MJ, Segal A, Robins P, Byrne MJ. Nowak AK, et al. Among authors: segal a. Clin Cancer Res. 2010 Apr 15;16(8):2409-17. doi: 10.1158/1078-0432.CCR-09-2313. Epub 2010 Apr 6. Clin Cancer Res. 2010. PMID: 20371686 Clinical Trial.

3

A diagnosis of malignant pleural mesothelioma can be made by effusion cytology: results of a 20 year audit.

Segal A, Sterrett GF, Frost FA, Shilkin KB, Olsen NJ, Musk AW, Nowak AK, Robinson BW, Creaney J. Segal A, et al. Pathology. 2013 Jan;45(1):44-8. doi: 10.1097/PAT.0b013e32835bc848. Pathology. 2013. PMID: 23222247

4

Bilateral thoracoscopy, mediastinoscopy and laparoscopy, in addition to CT, MRI and PET imaging, are essential to correctly stage and treat patients with mesothelioma prior to trimodality therapy.

Alvarez JM, Hasani A, Segal A, Sterret G, Millward M, Nowak A, Musk W, Bydder S. Alvarez JM, et al. Among authors: segal a. ANZ J Surg. 2009 Oct;79(10):734-8. doi: 10.1111/j.1445-2197.2009.05060.x. ANZ J Surg. 2009. PMID: 19878170

5

Comparison of outcomes following a cytological or histological diagnosis of malignant mesothelioma.

Muruganandan S, Alfonso H, Franklin P, Shilkin K, Segal A, Olsen N, Reid A, de Klerk N, Musk AB, Brims F. Muruganandan S, et al. Among authors: segal a. Br J Cancer. 2017 Mar 14;116(6):703-708. doi: 10.1038/bjc.2017.20. Epub 2017 Feb 14. Br J Cancer. 2017. PMID: 28196068 Free PMC article.

6

Histopathology of removed indwelling pleural catheters from patients with malignant pleural diseases.

Tobin CL, Thomas R, Chai SM, Segal A, Lee YC. Tobin CL, et al. Among authors: segal a. Respirology. 2016 Jul;21(5):939-42. doi: 10.1111/resp.12777. Epub 2016 Mar 19. Respirology. 2016. PMID: 26994412

7

A Novel Clinical Prediction Model for Prognosis in Malignant Pleural Mesothelioma Using Decision Tree Analysis.

Brims FJ, Meniawy TM, Duffus I, de Fonseka D, Segal A, Creaney J, Maskell N, Lake RA, de Klerk N, Nowak AK. Brims FJ, et al. Among authors: segal a. J Thorac Oncol. 2016 Apr;11(4):573-82. doi: 10.1016/j.jtho.2015.12.108. Epub 2016 Jan 8. J Thorac Oncol. 2016. PMID: 26776867 Free article.

8

Characterization of hypoxia in malignant pleural mesothelioma with FMISO PET-CT.

Francis RJ, Segard T, Morandeau L, Lee YC, Millward MJ, Segal A, Nowak AK. Francis RJ, et al. Among authors: segal a. Lung Cancer. 2015 Oct;90(1):55-60. doi: 10.1016/j.lungcan.2015.07.015. Epub 2015 Jul 30. Lung Cancer. 2015. PMID: 26259878

9

Pleural fluid mesothelin as an adjunct to the diagnosis of pleural malignant mesothelioma.

Creaney J, Segal A, Olsen N, Dick IM, Musk AW, Skates SJ, Robinson BW. Creaney J, et al. Among authors: segal a. Dis Markers. 2014;2014:413946. doi: 10.1155/2014/413946. Epub 2014 Nov 23. Dis Markers. 2014. PMID: 25505814 Free PMC article.

10

A commercially available preparation of Staphylococcus aureus bio-products potently inhibits tumour growth in a murine model of mesothelioma.

Lansley SM, Varano Della Vergiliana JF, Cleaver AL, Ren SH, Segal A, Xu MY, Lee YC. Lansley SM, et al. Among authors: segal a. Respirology. 2014 Oct;19(7):1025-33. doi: 10.1111/resp.12351. Epub 2014 Aug 14. Respirology. 2014. PMID: 25123375 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results